Further queries of datasets for melanoma-related genetic/epigenetic changes in RIPK4 (http://www.cbioportal.org/data_sets.jsp, including the TCGA through the cBIO Portal for Cancer Genomics, accessed data 15 June 2020) demonstrated a low (6%) incidence of missense RIPK4 mutations in melanoma (Figure 1f and Supplementary Figure S1) and a reverse correlation between RIPK4 levels and methylation levels of RIPK4-encoding regions in melanoma samples (Figure 1h). Here, RIPK4 is linked to melanoma.